André Paternò Castello Dias Carneiro

GU Medical Oncologist at Hospital Israelita Albert Einstein (@hosp_einstein); LACOG member (@lacog_group); Tweets are my own.

[André Paternò Castello Dias Carneiro @andrepcdc]

@mzugman @SalvadorjcMD @ASCO @montypal @FoundationATCG @paulovcamp @COHMedOnc @hosp_einstein @PGrivasMDPhD @OncBrothers @neerajaiims @NazliDizman Congrats!! 👏🏻👏🏻👏🏻

[André Paternò Castello Dias Carneiro @andrepcdc]

Our BRA-Bladder 🇧🇷 (just out in JCO Global Oncology): huge gap between guidelines and reality in localized bladder cancer across middle-income settings. Pts aren’t failing guidelines — systems are failing patients. Access > innovation in many settings.
https://t.co/XnVFX4wrmu

[André Paternò Castello Dias Carneiro @andrepcdc]

7–1–1 ODAC vote for capivasertib in PTEN-deficient mHSPC.

Modest rPFS (HR 0.81), OS negative/immature, ↑ toxicity.

Are we lowering the bar for biomarker-driven approvals?

This feels like biology > clinical benefit.

Let’s see how the FDA spins the label.

[Katy Beckermann @katy_beckermann]

ODAC voted 7-1-1 today in favor of capivasertib + abiraterone for PTEN-deficient mHSPC.
The vote came despite a negative immature OS readout, which is the real story.

CAPItello-281 (n=1012): 🎯 PTEN-deficient mHSPC, biomarker-selected
📈 rPFS 33.2 vs 25.7 mo, HR 0.81, P=0.034
❓ OS HR 0.90, P=0.40 (immature, 26.4% maturity) ⚠️ Serious AEs 42.5% vs 26.0%

Worth watching how the FDA responds and how they label the indication, including which companion PTEN assay is required.

Adoption in clinic will hinge on testing access and proactive AE management as much as the label itself.
📄 https://t.co/jynqMt5EGT

#ProstateCancer #mHSPC #GUonc #ODAC #FOAMonc

[Miguel Zugman, MD @mzugman]

Always a privilege to watch Dr. @montypal present — especially in a year with so many remarkable developments at #ASCOGU26
Proud to have learned from him up close during my time at @cityofhope, and hoping now to generate high-quality data with my skilled Brazilian colleagues.

[André Paternò Castello Dias Carneiro @andrepcdc]

@mzugman @montypal @brian_rini @DrTHut @elena_verzoni @tompowles1 @DrChoueiri @neerajaiims @OncJournal @DrIacovelli Awesome @mzugman!! Congrats, and see you next week!

[André Paternò Castello Dias Carneiro @andrepcdc]

Finally IO/IO emerging as an option for fav risk disease! Selection is key and an unmet need (biomarkers), but not considering this strategy deprive some fav risk pts of having long term benefits.

[Yüksel Ürün @DrYukselUrun]

Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment, and follow-up!
@myESMO @tompowles1 @AlbigesL @ViktorGruenwald @ravikanesvaran @DrRanaMcKay @g_procopio_ @Silke_Gillessen @crisuarez08 @jteoh_hk @g_develasco @OncoAlert @kidneycan @KidneyCancer
https://t.co/3ST5FzknL6

[André Paternò Castello Dias Carneiro @andrepcdc]

@DrYukselUrun @myESMO @tompowles1 @AlbigesL @ViktorGruenwald @ravikanesvaran @DrRanaMcKay @g_procopio_ @Silke_Gillessen @crisuarez08 @jteoh_hk @g_develasco @OncoAlert @kidneycan @KidneyCancer @DrChoueiri @neerajaiims @montypal @ZiadBakouny @FabioSchutz78 @BourlonMaite @TiansterZhang @HHammersMD @brian_rini @KatsuakiMaehara Finally IO/IO emerging as an option for fav risk disease! Selection is key and an unmet need (biomarkers), but not considering this strategy deprive some fav risk pts of having long term benefits.

[André Paternò Castello Dias Carneiro @andrepcdc]

@AzadOncology @brookmans76 @UrolOncol @anis_a_hamid @ChrisSweens1 @PeterMacRes Exceptional work, very important review on prostate cancer and precision medicine. Kudos for everyone involved 👏🏻👏🏻

[André Paternò Castello Dias Carneiro @andrepcdc]

@brookmans76 bizarre... to say the least

[André Paternò Castello Dias Carneiro @andrepcdc]

Great honor to be part of this important paper around mUC and the role of IO combos in 1L. Thanks @fsabino_onco for the leadership. Amazing!!

[Fernando Sabino, MD, PhD @fsabino_onco]

⚡️Just out at @CHematology the 1st systematic review and NMA with immune-combos in 1st line mUC (including the data of EV-302 just published).
https://t.co/w9njJWqqmB

@SoaresAndrey @fmassari79 @vmollica7 @BourlonMaite @shilpaonc @asasse @andrepcdc

[André Paternò Castello Dias Carneiro @andrepcdc]

@APConley77 @jalivingston_md @MCT_AACR @EpicentRx @MDAndersonNews @VivekSubbiah @PestanaRC

[André Paternò Castello Dias Carneiro @andrepcdc]

As ADCs come into play and precision medicine evolves, it becomes more important to improve patient selection for therapies in aUC. Great study on the expression of TROP2 and NECTIN-4, by @Markuseckstein3 and colleagues. Maybe ADCs are not for everyone.

https://t.co/iWNXtMS0lg

[André Paternò Castello Dias Carneiro @andrepcdc]

@brian_rini @montypal @PGrivasMDPhD @TiansterZhang @HHammersMD @ERPlimackMD @neerajaiims @shilpaonc @Uromigos @DrChoueiri @drenriquegrande Awesome! But mDOR I think is also important to be considered

[André Paternò Castello Dias Carneiro @andrepcdc]

Very nice discussion today around papillary renal cell carcinoma with the @cityofhope dream team represented by the amazing @montypal. Congrats @glaucia_asc for the presentation 🇧🇷🇺🇸

[André Paternò Castello Dias Carneiro @andrepcdc]

@mendesthiagob Loads of Beta blockers

[André Paternò Castello Dias Carneiro @andrepcdc]

@drfuzita @DVAraujoMD

[André Paternò Castello Dias Carneiro @andrepcdc]

Excellent mRCC discussion today with dear friends at @LACOG_group meeting (GU Review). Great to have @BourlonMaite 🇲🇽 on board sharing her thoughts as well!

[André Paternò Castello Dias Carneiro @andrepcdc]

“Why It Takes Forever to Get a Doctor's Appointment | Time”. What a great summary of the endless storm we face daily. By ⁦@ilanayurkiewicz⁩ https://t.co/S4glGXk6fY

[André Paternò Castello Dias Carneiro @andrepcdc]

Here we gooo #ASCO23

[André Paternò Castello Dias Carneiro @andrepcdc]

@PestanaRC Yep